Skip to content
type1.science

MiniMed Fit (patch pump)

MiniMed

MiniMed's first tubeless ("patch") insulin pump — a semi-durable design pairing a rechargeable reusable base with a disposable component, holding 300 units and worn for up to 7 days. Built to run the same phone-controlled, Vivera closed-loop algorithm and Simplera Sync / Instinct sensor ecosystem as the tubed MiniMed Flex. Reported FDA submission target is fall 2026, with U.S. availability not expected before 2027 — and conference reporting from ADA 2026 points to a commercial launch as late as 2028. The timeline is uncertain and most specifications are pre-clearance, manufacturer-stated figures.

On the horizonEarly evidencepumptubelesspatchphone-control

The scorecard

Interoperability55

Planned to work with Medtronic's Simplera Sync and Abbott-built Instinct sensors via the shared Flex/Vivera ecosystem, but it is a closed proprietary system with no DIY/open-protocol support and unproven cross-CGM breadth pre-launch.

Reliability45

No published precision, occlusion-detection or human-factors data yet. The Vivera algorithm it will run has cleared FDA to begin its pivotal trial, and small adult feasibility work reported at ADA 2026 looked encouraging (mean time-in-range 73.8% with no user input), but that is early feasibility data on the algorithm — not pivotal data, and not the pump hardware. The track record is still essentially pre-market.[1]

Form factor85

Genuinely tubeless patch worn on-body for up to 7 days; semi-durable (reusable rechargeable base + disposable part) is slightly less seamless than a fully disposable pod but reduces per-wear waste.

Phone control80

Designed around app-only control consistent with the sibling MiniMed Flex (no screen, fully phone-operated), implying phone bolusing — but the dedicated Fit app is unreleased and unverified.

Capacity85

300-unit reservoir is ~50% larger than typical patch pumps, with 7-day wear and a rechargeable battery rated beyond one wear cycle (two batteries supplied) — strong for a tubeless device.

Access & cost18

Not yet submitted to FDA (target fall 2026) and not expected on the U.S. market before 2027 — conference reporting from ADA 2026 puts the commercial launch as late as 2028. No pricing, reimbursement or ex-US availability confirmed.[1]

The full picture

The MiniMed Fit is MiniMed's first tubeless "patch" insulin pump — its bid to compete in a category long dominated by Insulet's Omnipod.1 It is described as a tubeless, patch-style system worn directly on the body, doing away with the tubing and separate handset of a traditional pump.2

A note on the name: this is the diabetes business that used to be Medtronic Diabetes. It was carved out as MiniMed Group, Inc., which listed on Nasdaq (ticker MMED) in March 2026, with Medtronic retaining roughly 90% of the shares pending a later distribution.3 The product and the pipeline are the same; the company badge on them is now MiniMed.

Form factor and wear

Unlike Insulet's fully disposable Omnipod, the Fit uses a semi-durable, two-piece design: a rechargeable, reusable electronics base plus a disposable reservoir-and-adhesive component.4 MiniMed supplies two rechargeable batteries, each rated to last longer than a full wear cycle, so one charges while the other is in use.5 The reservoir holds 300 units of insulin — roughly 50% more than many patch pumps today — and the device is rated for up to 7-day wear.6 The pump was developed in-house rather than acquired; an earlier plan to buy patch-pump maker EOFlow for about $738 million was abandoned in December 2023 amid a patent dispute with Insulet, after which Medtronic Diabetes continued building its own.7

Infusion, occlusion detection and reliability

Detailed specifications for the cannula/infusion set and the occlusion-detection system have not been published, and there is no peer-reviewed precision or reliability data yet.8 The controlling Vivera algorithm has only recently received FDA clearance to begin its pivotal trial, so real-world performance, alarms and occlusion handling remain unproven.9 These figures should be read as manufacturer-stated, pre-clearance claims.

CGM, algorithm and DIY compatibility

The Fit is built to share the same algorithm and sensor ecosystem as the tubed MiniMed Flex.10 That means it is intended to run on MiniMed's Vivera algorithm — described as a third-generation full closed-loop system that can bolus automatically for meals or let the user choose a simple meal announcement or full carb count — alongside the Simplera Sync disposable sensor and the Abbott-built Instinct sensor.11 The Simplera Sync, an all-in-one disposable CGM, was FDA-approved for MiniMed's automated insulin delivery system in April 2025.12 As a closed, proprietary system, the Fit is not compatible with DIY/open-source loops.

Vivera is the part of this stack with any human data at all, and even that is thin. Conference reporting from ADA 2026 describes an adult feasibility study in which Vivera reached a mean time-in-range of 73.8% with no user input at all, rising to 82.3% when users chose to count carbs.13 Read those numbers carefully: a feasibility study is small, short and not designed to prove anything — the pivotal trial has only just been cleared to start, and none of this was measured on the Fit patch pump itself.

Phone bolusing

MiniMed's next-generation pumps are moving to app-only control: the sibling MiniMed Flex has no screen and is operated entirely from a phone, and the Fit is expected to follow the same phone-first model — implying phone bolusing.14 The dedicated app, however, is unreleased and its features unverified.

Access and cost

The Fit is not yet on the market, and it is not close. The company has reportedly targeted an FDA submission by fall 2026, with analysts expecting U.S. availability no earlier than 2027.15 Conference reporting from ADA 2026 goes further and points to a commercial launch in 2028 — that is reporting from a conference roundup, not a company commitment, but it is the most specific launch estimate in circulation and it is later than the 2027 figure.13 No pricing, insurance coverage or non-US (UK/EU) availability has been confirmed; the company has signalled a dual pharmacy and durable-medical-equipment distribution approach.16

If you are choosing a pump now, the honest framing is: the Fit is not a device you can plan around. Anyone who needs a tubeless pump in the next year or two is choosing between what is already shipping.

What's coming

The near-term milestones are the Vivera pivotal trial and the planned fall-2026 FDA submission, both of which will determine whether even the 2027 availability estimate holds — and the sharpest launch estimate available (2028) is later than that.1713 Until clearance, every specification here — reservoir size, wear time, occlusion handling, phone bolusing — is a manufacturer or analyst projection, not validated performance. Treat the timeline as uncertain.

References

  1. MassDevice. Next-gen Medtronic insulin pump reportedly set for FDA submission, patch pump on the way. MassDevice (2025). https://www.massdevice.com/next-gen-medtronic-insulin-pump-fda-submission-2026/ ↩

  2. Drug Delivery Business News. Medtronic Diabetes to submit patch pump to FDA by fall 2026. Drug Delivery Business News (2025). https://www.drugdeliverybusiness.com/medtronics-patch-fda-minimed-on-track/ ↩

  3. MiniMed. MiniMed to begin trading on Nasdaq Global Select Market (6 March 2026). https://news.medtronic.com/2026-03-06-MiniMed-to-begin-trading-on-Nasdaq-Global-Select-Market — the IPO priced at $20/share and closed 9 March 2026; MiniMed Group, Inc. trades on Nasdaq as MMED, with Medtronic retaining approximately 90% of shares pending a later distribution. ↩

  4. MedTech Dive. ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors. MedTech Dive (2025). https://www.medtechdive.com/news/ada-conference-diabetes-new-pumps-cgms/751482/ ↩

  5. Drug Delivery Business News. Next-gen Medtronic insulin pump reportedly set for FDA submission. Drug Delivery Business News (2025). https://www.drugdeliverybusiness.com/next-gen-medtronic-insulin-pump-fda-submission-2026/ ↩

  6. MedTech Dive. ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors. MedTech Dive (2025). https://www.medtechdive.com/news/ada-conference-diabetes-new-pumps-cgms/751482/ ↩

  7. Drug Delivery Business News. Medtronic nixes $738M deal for insulin patch pump maker EOFlow. Drug Delivery Business News (2023). https://www.drugdeliverybusiness.com/medtronic-nixes-738m-deal-for-insulin-patch-pump-maker-eoflow/ ↩

  8. Drug Delivery Business News. Medtronic Diabetes to submit patch pump to FDA by fall 2026. Drug Delivery Business News (2025). https://www.drugdeliverybusiness.com/medtronics-patch-fda-minimed-on-track/ ↩

  9. Diabetech. Medtronic Says MiniMed Spinoff Will Not Delay Next-Gen Pump Launches. Diabetech (2025). https://www.diabetech.info/p/medtronic-says-next-gen-flex-and-fit-insulin-pumps-remain-on-schedule-with-new-sensors-and-algorithm ↩

  10. Diabetech. Medtronic Says MiniMed Spinoff Will Not Delay Next-Gen Pump Launches. Diabetech (2025). https://www.diabetech.info/p/medtronic-says-next-gen-flex-and-fit-insulin-pumps-remain-on-schedule-with-new-sensors-and-algorithm ↩

  11. MedTech Dive. ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors. MedTech Dive (2025). https://www.medtechdive.com/news/ada-conference-diabetes-new-pumps-cgms/751482/ ↩

  12. Medtronic. New Simplera Sync sensor for the MiniMed 780G System now FDA approved. Medtronic News (2025). https://news.medtronic.com/2025-04-18-New-Simplera-Sync-TM-sensor-for-the-MiniMed-TM-780G-System-now-FDA-approved ↩

  13. Diabetotech. Closed-loop updates from ADA 2026. Diabetotech (2026). https://www.diabetotech.com/blog/closed-loop-updates-from-ada-2026 — conference roundup; source for the 2028 launch target and the Vivera adult feasibility time-in-range figures. Not a company statement and not published trial data. ↩ ↩2 ↩3

  14. Diabetech. Medtronic Submits MiniMed Flex Pump to the FDA & Tests New Algorithm. Diabetech (2025). https://www.diabetech.info/p/medtronic-submits-minimed-flex-to-the-fda-begins-tests-on-a-next-gen-algorithm ↩

  15. MedTech Dive. ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors. MedTech Dive (2025). https://www.medtechdive.com/news/ada-conference-diabetes-new-pumps-cgms/751482/ ↩

  16. Drug Delivery Business News. Next-gen Medtronic insulin pump reportedly set for FDA submission. Drug Delivery Business News (2025). https://www.drugdeliverybusiness.com/next-gen-medtronic-insulin-pump-fda-submission-2026/ ↩

  17. Drug Delivery Business News. Medtronic Diabetes to submit patch pump to FDA by fall 2026. Drug Delivery Business News (2025). https://www.drugdeliverybusiness.com/medtronics-patch-fda-minimed-on-track/ ↩

Coming soon

ETA · FDA submission targeted fall 2026; US availability not expected before 2027, and conference reporting from ADA 2026 points to a commercial launch as late as 2028 (not cleared; timeline uncertain)

  • →Vivera algorithm pivotal trial (cleared by FDA to begin)
  • →Planned FDA submission of the patch pump · fall 2026
  • →Commercial launch (not cleared). Analysts say no earlier than 2027; ADA 2026 conference reporting points to 2028 · 2027 at the earliest, possibly 2028

Sources

  1. [1]Closed-Loop Updates from ADA 2026 · conference — Conference roundup, not a company statement — the source for the 300-unit / 7-day patch description, the 2028 launch target and the Vivera adult feasibility time-in-range figures (73.8% hands-free, 82.3% with optional carb counting). Treat as reporting, not published trial data.
  2. [2]MiniMed Diabetes to submit patch pump to FDA by fall 2026 · news
  3. [3]MiniMed to begin trading on Nasdaq Global Select Market · manufacturer · 2026-03-06